Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New drug ACTM-838 tested in patients with Hard-to-Treat cancers

NCT ID NCT06336148

First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 28 times

Summary

This early-phase study tested a new drug called ACTM-838 in 10 people with advanced solid tumors that no longer responded to standard treatments. The main goals were to check safety and find the right dose. The study was stopped early, so results are limited.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Alfred Hospital, 55 Commercial Road, Site No: 201

    Melbourne, Victoria, 3004, Australia

  • Southern Oncology Clinical Research Unit, Level 3, Mark Oliphant Building, 5 Laffer Drive, Site No: 202

    Bedford Park, South Australia, 5042, Australia

  • UPMC Hillman Cancer Center, 5115 Centre Ave

    Pittsburgh, Pennsylvania, 15232, United States

  • University of Southern California Norris Comprehensive Cancer Center, 1441 Eastlake Ave.

    Los Angeles, California, 90033, United States

  • Westmead Hospital, Cnr Hawkesbury Road and Darcy Road, Site No: 200

    Westmead, New South Wales, 2145, Australia

Conditions

Explore the condition pages connected to this study.